SEC Form DEF 14A filed by Supernus Pharmaceuticals Inc.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SECURITIES EXCHANGE ACT OF 1934
9715 Key West Avenue
Rockville, MD 20850
(301) 838-2500
VIRTUAL MEETING ONLY
TO BE HELD AT 10:00 A.M. EDT, ON
JUNE 16, 2025
![[MISSING IMAGE: sg_jackakhattarnew1-bw.jpg]](https://www.sec.gov/Archives/edgar/data/0001356576/000110465925042531/sg_jackakhattarnew1-bw.jpg)
9715 Key West Avenue
Rockville, MD 20850
(301) 838-2500
| |
VOLUNTARY ELECTRONIC RECEIPT OF PROXY MATERIALS
Supernus is pleased to deliver proxy materials electronically via the internet. Electronic delivery allows Supernus to provide you with the information you need for the Annual Meeting in a fast and convenient medium while reducing costs.
We encourage our shareholders to elect to receive all proxy materials (including the notice of availability of such materials) electronically.
|
| | ||||
| |
Shareholders of Record
Enroll at: www.investorvote.com/SUPN
|
| | |
Beneficial Owners
Enroll by contacting your broker
|
| |
Name and Address of Beneficial Owner
|
| |
Number of Shares of
Common Stock Beneficially Owned |
| |
Percentage of Shares
of Common Stock Beneficially Owned |
| ||||||
5% Stockholders: | | | | | | | | | | | | | |
BlackRock, Inc. and its affiliates(1)
50 Hudson Yards New York, NY 10001 |
| | | | 8,197,023 | | | | | | 14.6% | | |
The Vanguard Group and its affiliates(2)
100 Vanguard Blvd. Malvern, PA 19355 |
| | | | 6,214,731 | | | | | | 11.1% | | |
Armistice Capital, LLC(3)
510 Madison Avenue, 7th Floor New York, NY 10022 |
| | | | 4,836,000 | | | | | | 8.6% | | |
Dimensional Fund Advisors LP(4)
6300 Bee Cave Road, Building One, Austin, TX 78746 |
| | | | 2,882,505 | | | | | | 5.2% | | |
Macquarie Group Limited and its affiliates(5)
50 Martin Place Sydney, New South Wales, Australia |
| | | | 2,631,897 | | | | | | 4.7% | | |
Executive Officers and Directors: | | | | | | | | | | | | | |
Jack A. Khattar+(6)
|
| | | | 4,033,533 | | | | | | 7.0% | | |
Timothy C. Dec+(7)
|
| | | | 127,681 | | | | | | * | | |
Padmanabh P. Bhatt, Ph.D.+(8)
|
| | | | 110,454 | | | | | | * | | |
Jonathan Rubin, M.D.+(9)
|
| | | | 84,634 | | | | | | * | | |
Frank Mottola+(10)
|
| | | | 141,901 | | | | | | * | | |
Carrolee Barlow, M.D., Ph.D.(11)
|
| | | | 83,272 | | | | | | * | | |
Georges Gemayel, Ph.D.(12)
|
| | | | 106,727 | | | | | | * | | |
Frederick M. Hudson(13)
|
| | | | 141,807 | | | | | | * | | |
Charles W. Newhall, III(14)
|
| | | | 223,687 | | | | | | * | | |
Bethany L. Sensenig(16)
|
| | | | 19,659 | | | | | | * | | |
All executive officers and directors as a group (10 persons)
|
| | | | 5,073,356 | | | | | | 8.8% | | |
ELECTION OF DIRECTORS
Name
|
| |
Age
|
| |
Director Since
|
| |
Position
|
| ||||||
Class I Directors (Term maturing in 2025) | | | | | | | | | | | | | | | | |
Carrolee Barlow, M.D., Ph.D.(1)(4)
|
| | | | 61 | | | | | | 2018 | | | | Director | |
Jack A. Khattar
|
| | | | 63 | | | | | | 2005 | | | | President, Chief Executive Officer and Secretary, Director | |
Class II Directors (Term maturing in 2026): | | | | | | | | | | | | | | | | |
Frederick M. Hudson(2)(3)
|
| | | | 79 | | | | | | 2010 | | | | Director | |
Charles W. Newhall, III(3)(4)
|
| | | | 80 | | | | | | 2005 | | | | Director | |
Class III Directors (Term maturing in 2027): | | | | | | | | | | | | | | | | |
Georges Gemayel, Ph.D.(1)(2)(3)(4)
|
| | | | 64 | | | | | | 2015 | | | | Director | |
Bethany L. Sensenig(2)
|
| | | | 49 | | | | | | 2023 | | | | Director | |
Name
|
| |
Age
|
| |
Position(s)
|
| |||
Jack A. Khattar
|
| | | | 63 | | | |
President, Chief Executive Officer & Secretary, Director
|
|
Timothy C. Dec
|
| | | | 66 | | | | Senior Vice President, Chief Financial Officer | |
Padmanabh P. Bhatt, Ph.D.
|
| | | | 67 | | | | Senior Vice President of Intellectual Property, Chief Scientific Officer | |
Frank Mottola
|
| | | | 53 | | | | Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs | |
Jonathan Rubin, M.D.
|
| | | | 63 | | | | Senior Vice President, Chief Medical Officer, Research and Development | |
| | ACADIA Pharmaceuticals Inc. | | | | ANI Pharmaceuticals, Inc. | | | | Emergent Biosolutions Inc. | | | | Ligand Pharmaceuticals Incorporated | | |
| | Alkermes Plc | | | | Collegium Pharmaceutical, Inc. | | | | Halozyme Therapeutics, Inc. | | | |
Pacira Biosciences, Inc.
|
| |
| | Amicus Therapeutics, Inc. | | | | Corcept Therapeutics Incorporated | | | | Harmony Biosciences Holdings, Inc. | | | |
PTC Therapeutics, Inc.
|
| |
| | Amphastar Pharmaceuticals, Inc. | | | | Dynavax Technologies Corporation | | | | Ironwood Pharmaceuticals, Inc. | | | | Ultragenyx Pharmaceutical Inc. | | |
| | |
Base Salary
|
| |
Percentage
Change |
| ||||||||||||
Name
|
| |
2023
|
| |
2024
|
| ||||||||||||
Jack A. Khattar
|
| | | $ | 963,000 | | | | | $ | 1,001,500 | | | | | | 4.0% | | |
Timothy C. Dec
|
| | | $ | 453,800 | | | | | $ | 485,500 | | | | | | 7.0% | | |
Padmanabh P. Bhatt, Ph.D.
|
| | | $ | 427,700 | | | | | $ | 440,500 | | | | | | 3.0% | | |
Jonathan Rubin, M.D.
|
| | | $ | 440,000 | | | | | $ | 466,400 | | | | | | 6.0% | | |
Frank Mottola
|
| | | $ | 352,700 | | | | | $ | 377,400 | | | | | | 7.0% | | |
| | |
Target Bonus
as a % of Base Salary) |
| |
Weighting of
Objectives |
| ||||||||||||
Name
|
| |
Company
|
| |
Individual
|
| ||||||||||||
Jack A. Khattar
|
| | | | 75% | | | | | | 100% | | | | | | 0%(1) | | |
Timothy C. Dec
|
| | | | 45% | | | | | | 60% | | | | | | 40% | | |
Padmanabh P. Bhatt, Ph.D.
|
| | | | 35% | | | | | | 60% | | | | | | 40% | | |
Jonathan Rubin, M.D.
|
| | | | 40% | | | | | | 60% | | | | | | 40% | | |
Frank Mottola
|
| | | | 35% | | | | | | 60% | | | | | | 40% | | |
Frederick M. Hudson,
Charles W. Newhall, III
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Stock
Awards ($)(1) |
| |
Option
Awards ($)(2) |
| |
Non-Equity
Incentive Plan Compensation ($)(3) |
| |
All Other
Compensation ($)(4) |
| |
Total
($) |
| |||||||||||||||||||||
Jack A. Khattar
Chief Executive Officer, President & Secretary |
| | | | 2024 | | | | | | 1,006,105 | | | | | | 5,199,012 | | | | | | 5,567,427 | | | | | | 826,254 | | | | | | 50,195 | | | | | | 17,848,004 | | |
| | | 2023 | | | | | | 963,000 | | | | | | 4,760,000 | | | | | | 6,675,200 | | | | | | 830,588 | | | | | | 49,305 | | | | | | 13,278,093 | | | ||
| | | 2022 | | | | | | 913,500 | | | | | | 3,616,250 | | | | | | 4,767,500 | | | | | | 685,125 | | | | | | 30,342 | | | | | | 10,012,717 | | | ||
Timothy C. Dec
Senior Vice President, Chief Financial Officer |
| | | | 2024 | | | | | | 486,821 | | | | | | 658,200 | | | | | | 864,507 | | | | | | 229,160 | | | | | | 56,160 | | | | | | 2,953,048 | | |
| | | 2023 | | | | | | 453,800 | | | | | | 726,000 | | | | | | 953,600 | | | | | | 210,588 | | | | | | 39,639 | | | | | | 2,383,597 | | | ||
| | | 2022 | | | | | | 412,500 | | | | | | 151,190 | | | | | | 476,750 | | | | | | 178,200 | | | | | | 44,730 | | | | | | 1,263,370 | | | ||
Jonathan Rubin, MD
Senior Vice President, Chief Medical Officer Research and Development |
| | | | 2024 | | | | | | 467,500 | | | | | | 341,525 | | | | | | 432,254 | | | | | | 192,530 | | | | | | 50,274 | | | | | | 1,825,608 | | |
| | | 2023 | | | | | | 440,000 | | | | | | 448,000 | | | | | | 476,800 | | | | | | 184,448 | | | | | | 38,081 | | | | | | 1,587,329 | | | ||
| | | 2022 | | | | | | 412,000 | | | | | | 183,390 | | | | | | 476,750 | | | | | | 149,291 | | | | | | 33,357 | | | | | | 1,254,788 | | | ||
Padmanabh P. Bhatt, Ph.D.
Senior Vice President, Intellectual Property, Chief Scientific Officer |
| | | | 2024 | | | | | | 441,034 | | | | | | 274,250 | | | | | | 345,803 | | | | | | 163,434 | | | | | | 53,459 | | | | | | 1,552,229 | | |
| | | 2023 | | | | | | 427,700 | | | | | | 363,000 | | | | | | 476,800 | | | | | | 163,165 | | | | | | 37,546 | | | | | | 1,468,211 | | | ||
| | | 2022 | | | | | | 415,200 | | | | | | 183,390 | | | | | | 343,260 | | | | | | 140,973 | | | | | | 37,963 | | | | | | 1,120,759 | | | ||
Frank Mottola
Senior Vice President, Quality GMP Operations, Information Technology and Regulatory Affairs |
| | | | 2024 | | | | | | 378,429 | | | | | | 341,525 | | | | | | 432,254 | | | | | | 140,001 | | | | | | 53,215 | | | | | | 1,686,949 | | |
| | | 2023 | | | | | | 352,700 | | | | | | 544,500 | | | | | | 715,200 | | | | | | 129,361 | | | | | | 44,418 | | | | | | 1,786,179 | | | ||
| | | 2022 | | | | | | 342,400 | | | | | | 183,390 | | | | | | 343,260 | | | | | | 109,080 | | | | | | 39,393 | | | | | | 1,029,939 | | |
Name
|
| |
Grant Date
|
| |
Grant Type
|
| |
Estimated Future
Payouts Under Non-Equity Incentive Plan Awards |
| |
Estimated Future
Payouts Under Equity Incentive Plan Awards |
| |
Exercise
or Base Price of Option Awards ($/Sh)(2) |
| |
Grant
Date Fair Value of Stock and Option Awards ($)(3) |
| ||||||||||||||||||||||||||||||||||||||||||
|
Threshold
($) |
| |
Target
($)(1) |
| |
Maximum
($) |
| |
Threshold
(#) |
| |
Target
(#) |
| |
Maximum
(#) |
| ||||||||||||||||||||||||||||||||||||||||||||
Jack A. Khattar
|
| | | | 2/22/2024 | | | | | | Cash | | | | | | — | | | | | | 751,125 | | | | | | 751,125 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 2/22/2024 | | | | | | Options | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 322,000 | | | | | | 322,000 | | | | | | 27.94 | | | | | | 5,567,427 | | |
| | | | | 6/24/2024(4) | | | | | | PSUs | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 193,200 | | | | | | 193,200 | | | | | | — | | | | | | 5,199,012 | | |
Timothy C. Dec
|
| | | | 2/23/2023 | | | | | | Cash | | | | | | — | | | | | | 218,475 | | | | | | 218,475 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 2/23/2023 | | | | | | Options | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 50,000 | | | | | | 50,000 | | | | | | 27.94 | | | | | | 864,507 | | |
| | | | | 2/23/2023 | | | | | | RSUs | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 12,000 | | | | | | 12,000 | | | | | | — | | | | | | 335,280 | | |
| | | | | 6/24/2024(4) | | | | | | PSUs | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 12,000 | | | | | | 12,000 | | | | | | — | | | | | | 322,920 | | |
Jonathan Rubin, MD
|
| | | | 2/22/2024 | | | | | | Cash | | | | | | — | | | | | | 186,560 | | | | | | 186,560 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 2/22/2024 | | | | | | Options | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 25,000 | | | | | | 25,000 | | | | | | 27.94 | | | | | | 432,254 | | |
| | | | | 2/22/2024 | | | | | | RSUs | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,000 | | | | | | 5,000 | | | | | | — | | | | | | 139,700 | | |
| | | | | 6/24/2024(4) | | | | | | PSUs | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,500 | | | | | | 7,500 | | | | | | — | | | | | | 201,825 | | |
Padmanabh P. Bhatt, Ph.D.
|
| | | | 2/22/2024 | | | | | | Cash | | | | | | — | | | | | | 154,175 | | | | | | 154,175 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 2/22/2024 | | | | | | Options | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 20,000 | | | | | | 20,000 | | | | | | 27.94 | | | | | | 345,803 | | |
| | | | | 2/22/2024 | | | | | | RSUs | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,000 | | | | | | 5,000 | | | | | | — | | | | | | 139,700 | | |
| | | | | 6/24/2024(4) | | | | | | PSUs | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,000 | | | | | | 5,000 | | | | | | — | | | | | | 134,550 | | |
Frank Mottola
|
| | | | 2/22/2024 | | | | | | Cash | | | | | | — | | | | | | 132,090 | | | | | | 132,090 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 2/22/2024 | | | | | | Options | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 25,000 | | | | | | 25,000 | | | | | | 27.94 | | | | | | 432,254 | | |
| | | | | 2/22/2024 | | | | | | RSUs | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,000 | | | | | | 5,000 | | | | | | — | | | | | | 139,700 | | |
| | | | | 6/24/2024(4) | | | | | | PSUs | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,500 | | | | | | 7,500 | | | | | | — | | | | | | 201,825 | | |
| | |
Options Awards(1)
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||||||||||||||
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Option
Exercise Price ($)(2) |
| |
Option
Expiration Date |
| |
Number of
Shares or Units of Stock That Have Not Vested(1) |
| |
Market
Value of Shares or Units of Stock That Have Not Vested ($)(3) |
| |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that Have Not Vested (#)(4) |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights that Have Not Vested ($)(3) |
| ||||||||||||||||||||||||
Jack A. Khattar
|
| | | | 255,000 | | | | | | — | | | | | | 12.98 | | | | | | 3/1/2026 | | | | | | | | | | | | | | | | | | 20,000 | | | | | | 723,200 | | |
| | | | | 325,000 | | | | | | — | | | | | | 25.30 | | | | | | 2/24/2027 | | | | | | | | | | | | | | | | | | 25,000 | | | | | | 904,000 | | |
| | | | | 250,000 | | | | | | — | | | | | | 39.40 | | | | | | 2/14/2028 | | | | | | | | | | | | | | | | | | 35,000 | | | | | | 1,265,600 | | |
| | | | | 300,000 | | | | | | — | | | | | | 36.75 | | | | | | 2/22/2029 | | | | | | | | | | | | | | | | | | 154,560 | | | | | | 5,588,890 | | |
| | | | | 281,250 | | | | | | — | | | | | | 23.99 | | | | | | 2/21/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 150,000 | | | | | | 50,000 | | | | | | 29.61 | | | | | | 2/19/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 125,000 | | | | | | 125,000 | | | | | | 32.20 | | | | | | 2/22/2032 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 70,000 | | | | | | 210,000 | | | | | | 38.60 | | | | | | 2/23/2033 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | — | | | | | | 322,000 | | | | | | 27.94 | | | | | | 2/22/2034 | | | | | | | | | | | | | | | | | | | | | | | | | | |
Timothy C. Dec
|
| | | | 63,750 | | | | | | 21,250 | | | | | | 25.09 | | | | | | 8/23/2031 | | | | | | 1,000 | | | | | | 36,160 | | | | | | 6,000 | | | | | | 216,960 | | |
| | | | | 12,500 | | | | | | 12,500 | | | | | | 32.20 | | | | | | 2/22/2032 | | | | | | 7,500 | | | | | | 271,200 | | | | | | 12,000 | | | | | | 433,920 | | |
| | | | | 10,000 | | | | | | 30,000 | | | | | | 38.60 | | | | | | 2/23/2033 | | | | | | 12,000 | | | | | | 433,920 | | | | | | | | | | | | | | |
| | | | | — | | | | | | 50,000 | | | | | | 27.94 | | | | | | 2/22/2034 | | | | | | | | | | | | | | | | | | | | | | | | | | |
Jonathan Rubin, MD
|
| | | | 15,000 | | | | | | — | | | | | | 23.99 | | | | | | 2/21/2030 | | | | | | 1,500 | | | | | | 54,240 | | | | | | 750 | | | | | | 27,120 | | |
| | | | | 18,750 | | | | | | 6,250 | | | | | | 29.61 | | | | | | 2/19/2031 | | | | | | 3,750 | | | | | | 135,600 | | | | | | 6,750 | | | | | | 244,080 | | |
| | | | | 12,500 | | | | | | 12,500 | | | | | | 32.20 | | | | | | 2/22/2032 | | | | | | 5,000 | | | | | | 180,800 | | | | | | 5,625 | | | | | | 203,400 | | |
| | | | | 5,000 | | | | | | 15,000 | | | | | | 38.60 | | | | | | 2/23/2033 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | — | | | | | | 25,000 | | | | | | 27.94 | | | | | | 2/22/2034 | | | | | | | | | | | | | | | | | | | | | | | | | | |
Padmanabh P. Bhatt, Ph.D.
|
| | | | 30,000 | | | | | | — | | | | | | 39.40 | | | | | | 2/14/2028 | | | | | | 1,500 | | | | | | 52,240 | | | | | | 1,500 | | | | | | 54,240 | | |
| | | | | 35,000 | | | | | | — | | | | | | 36.75 | | | | | | 2/22/2029 | | | | | | 3,750 | | | | | | 135,600 | | | | | | 1,250 | | | | | | 45,200 | | |
| | | | | 12,750 | | | | | | 4,250 | | | | | | 29.61 | | | | | | 2/19/2031 | | | | | | 5,000 | | | | | | 180,800 | | | | | | 5,000 | | | | | | 180,800 | | |
| | | | | 9,000 | | | | | | 9,000 | | | | | | 32.20 | | | | | | 2/22/2032 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 5,000 | | | | | | 15,000 | | | | | | 38.60 | | | | | | 2/23/2033 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | — | | | | | | 20,000 | | | | | | 27.94 | | | | | | 2/22/2034 | | | | | | | | | | | | | | | | | | | | | | | | | | |
Frank Mottola
|
| | | | 14,000 | | | | | | — | | | | | | 12.98 | | | | | | 3/1/2026 | | | | | | 1,500 | | | | | | 54,240 | | | | | | 2,010 | | | | | | 72,682 | | |
| | | | | 15,000 | | | | | | — | | | | | | 25.30 | | | | | | 2/24/2027 | | | | | | 5,625 | | | | | | 203,400 | | | | | | 7,500 | | | | | | 271,200 | | |
| | | | | 10,000 | | | | | | — | | | | | | 39.40 | | | | | | 2/14/2028 | | | | | | 5,000 | | | | | | 180,800 | | | | | | 7,500 | | | | | | 271,200 | | |
| | | | | 14,000 | | | | | | — | | | | | | 36.75 | | | | | | 2/22/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 22,000 | | | | | | — | | | | | | 23.99 | | | | | | 2/21/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 12,750 | | | | | | 4,250 | | | | | | 29.61 | | | | | | 2/19/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 9,000 | | | | | | 9,000 | | | | | | 32.20 | | | | | | 2/22/2032 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 7,500 | | | | | | 22,500 | | | | | | 38.60 | | | | | | 2/23/2033 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | — | | | | | | 25,000 | | | | | | 27.94 | | | | | | 2/22/2034 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||
Name
|
| |
Number of Shares
Acquired On Exercise (#) |
| |
Value
Realized On Exercise ($) |
| |
Number of Shares
Acquired On Vesting (#) |
| |
Value
Realized On Vesting ($) |
| ||||||||||||
Jack A. Khattar
|
| | | | 250,000 | | | | | | 6,837,950 | | | | | | 108,640 | | | | | | 3,584,258 | | |
Timothy C. Dec
|
| | | | — | | | | | | — | | | | | | 3,000 | | | | | | 86,620 | | |
Jonathan Rubin, MD
|
| | | | — | | | | | | — | | | | | | 4,625 | | | | | | 150,704 | | |
Padmanabh P. Bhatt, Ph.D.
|
| | | | 120,000 | | | | | | 1,717,827 | | | | | | 3,250 | | | | | | 94,243 | | |
Frank Mottola
|
| | | | 15,000 | | | | | | 417,743 | | | | | | 3,615 | | | | | | 103,103 | | |
Name
|
| |
Benefit
|
| |
Termination
Upon a Restructuring |
| |
Termination
Without Cause or Resignation for Good Reason |
| |
Resignation
for Good Reason After a Change of Control |
| |||||||||
Jack A. Khattar
|
| | Base salary continuation | | | | $ | 1,502,250 | | | | | $ | 1,502,250 | | | | | $ | 1,502,250 | | |
| | | Bonus(1) | | | | $ | 830,588 | | | | | $ | 830,588 | | | | | $ | 830,588 | | |
| | | Continuation of benefits(2) | | | | $ | 29,020 | | | | | $ | 29,020 | | | | | $ | 29,020 | | |
| | | Total | | | | $ | 2,361,858 | | | | | $ | 2,361,858 | | | | | $ | 2,361,858 | | |
Timothy C. Dec
|
| | Base salary continuation | | | | $ | 485,500 | | | | | $ | 485,500 | | | | | $ | 485,500 | | |
| | | Bonus(3) | | | | $ | 210,558 | | | | | $ | 210,558 | | | | | $ | 210,558 | | |
| | | Continuation of benefits(4) | | | | $ | 18,445 | | | | | $ | 18,445 | | | | | $ | 18,445 | | |
| | | Total | | | | $ | 714,503 | | | | | $ | 714,503 | | | | | $ | 714,503 | | |
Jonathan Rubin, MD
|
| | Base salary continuation | | | | $ | 466,400 | | | | | $ | 466,400 | | | | | $ | 466,400 | | |
| | | Bonus(3) | | | | $ | 184,448 | | | | | $ | 184,448 | | | | | $ | 184,448 | | |
| | | Continuation of benefits(4) | | | | $ | 19,347 | | | | | $ | 19,347 | | | | | $ | 19,347 | | |
| | | Total | | | | $ | 670,195 | | | | | $ | 670,195 | | | | | $ | 670,195 | | |
Padmanabh P. Bhatt, Ph.D.
|
| | Severance | | | | $ | 220,250 | | | | | | | | | | | | | | |
Frank Mottola
|
| | Base salary continuation | | | | $ | 377,400 | | | | | $ | 377,400 | | | | | $ | 377,400 | | |
| | | Bonus(3) | | | | $ | 129,361 | | | | | $ | 129,361 | | | | | $ | 129,361 | | |
| | | Continuation of benefits(4) | | | | $ | 28,807 | | | | | $ | 28,807 | | | | | $ | 28,807 | | |
| | | Total | | | | $ | 535,568 | | | | | $ | 535,568 | | | | | $ | 535,568 | | |
Year | | | Summary Compensation Table Total for Jack Khattar(1) ($) | | | Compensation Actually Paid to Jack Khattar(1)(2)(3) ($) | | | Average Summary Compensation Table Total for Non-PEO NEOs(1) ($) | | | Average Compensation Actually Paid to Non-PEO NEOs(1)(2)(3) ($) | | | Value of Initial Fixed $100 Investment based on:(4) | | | Net Earnings ($ Millions) | | | Product Sales ($ Millions)(5) | | |||||||||||||||||||||||||||
| Total Shareholder Return (“TSR”) ($) | | | Peer Group TSR ($) | | ||||||||||||||||||||||||||||||||||||||||||||
(a) | | | (b) | | | (c) | | | (d) | | | (e) | | | (f) | | | (g) | | | (h) | | | (i) | | ||||||||||||||||||||||||
2024 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||
2023 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||
2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||
2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||
2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
2020
|
| |
2021
|
| |
2022-2024
|
|
|
James P. Kelly
|
| |
Timothy C. Dec
|
| |
Timothy C. Dec
|
|
|
Stefan K.F. Schwabe, M.D., Ph.D.
|
| |
Jonathan Rubin, MD
|
| |
Jonathan Rubin, MD
|
|
|
Padmanabh P. Bhatt, Ph.D.
|
| |
Padmanabh P. Bhatt, Ph.D.
|
| |
Padmanabh P. Bhatt, Ph.D.
|
|
|
Tami Martin, R.N., Esq.
|
| |
Tami Martin, R.N., Esq.
|
| |
Frank Mottola
|
|
|
Gregory S. Patrick
|
| |
James P. Kelly
|
| |
—
|
|
Year | | | Summary Compensation Table Total for Jack Khattar ($) | | | Exclusion of Stock Awards and Option Awards for Jack Khattar ($) | | | Inclusion of Equity Values for Jack Khattar ($) | | | Compensation Actually Paid to Jack Khattar ($) | | ||||||||||||
2024 | | | | | | | | | | ( | | | | | | | | | | | | |
Year | | | Average Summary Compensation Table Total for Non-PEO NEOs ($) | | | Average Exclusion of Stock Awards and Option Awards for Non-PEO NEOs ($) | | | Average Inclusion of Equity Values for Non-PEO NEOs ($) | | | Average Compensation Actually Paid to Non-PEO NEOs ($) | | ||||||||||||
2024 | | | | | | | | | | ( | | | | | | | | | | | | |
Year | | | Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Jack Khattar ($) | | | Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Jack Khattar ($) | | | Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Jack Khattar ($) | | | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Jack Khattar ($) | | | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Jack Khattar ($) | | | Total − Inclusion of Equity Values for Jack Khattar ($) | | ||||||||||||||||||
2024 | | | | | | | | | | ( | | | | | | | | | | | ( | | | | | | | | | | | | |
Year | | | Average Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Non- PEO NEOs ($) | | | Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Non-PEO NEOs ($) | | | Average Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Non-PEO NEOs ($) | | | Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Non- PEO NEOs ($) | | | Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non-PEO NEOs ($) | | | Total − Average Inclusion of Equity Values for Non- PEO NEOs ($) | | ||||||||||||||||||
2024 | | | | | | | | | | ( | | | | | | | | | | | ( | | | | | | | | | | | | |
Versus TSR
![[MISSING IMAGE: bc_companytsr-4c.jpg]](https://www.sec.gov/Archives/edgar/data/0001356576/000110465925042531/bc_companytsr-4c.jpg)
Versus Net Earnings
![[MISSING IMAGE: bc_netearning-4c.jpg]](https://www.sec.gov/Archives/edgar/data/0001356576/000110465925042531/bc_netearning-4c.jpg)
Versus Gross Product Sales
![[MISSING IMAGE: bc_productsales-4c.jpg]](https://www.sec.gov/Archives/edgar/data/0001356576/000110465925042531/bc_productsales-4c.jpg)
| | | | |
| | | | |
Name | | | Grant Date | | | Number of Securities Underlying the Award | | | Exercise Price of the Award | | | Grant Date Fair Value of the Award | | | Percentage Change in the Closing Market Price of the Securities Underlying the Award Between the Trading Day Ending Immediately Prior to the Disclosure of Material Nonpublic Information and the Trading Day Beginning Immediately Following the Disclosure of Material Nonpublic Information | | |||||||||||||||
Jack Khattar | | | | | 02/22/2024 | | | | | | | | | | $ | | | | | | | | | | | | | ||||
Timothy C. Dec | | | | | 02/22/2024 | | | | | | | | | | $ | | | | | | | | | | | | | ||||
Jonathan Rubin | | | | | 02/22/2024 | | | | | | | | | | $ | | | | | | | | | | | | | ||||
Padmanabh Bhatt | | | | | 02/22/2024 | | | | | | | | | | $ | | | | | | | | | | | | | ||||
Frank Mottola | | | | | 02/22/2024 | | | | | | | | | | $ | | | | | | | | | | | | |
Committee
|
| |
Chairman
($) |
| |
Member
($) |
| ||||||
Audit Committee
|
| | | | 25,000 | | | | | | 12,500 | | |
Compensation Committee
|
| | | | 20,000 | | | | | | 10,000 | | |
Governance and Nominating Committee
|
| | | | 12,000 | | | | | | 6,000 | | |
Science Committee
|
| | | | 20,000 | | | | | | 10,000 | | |
Name
|
| |
Fees Earned
or Paid in Cash ($) |
| |
Stock
Awards ($)(1) |
| |
Option
Awards ($)(1) |
| |
Total
($) |
| ||||||||||||
Georges Gemayel
|
| | | | 88,500(2) | | | | | | 150,010 | | | | | | 142,678 | | | | | | 381,188 | | |
Frederick M. Hudson
|
| | | | 85,000(3) | | | | | | 150,010 | | | | | | 142,678 | | | | | | 377,688 | | |
Charles W. Newhall, III
|
| | | | 107,000(4) | | | | | | 150,010 | | | | | | 142,678 | | | | | | 399,688 | | |
Carrolee Barlow, M.D., Ph.D.
|
| | | | 76,000(5) | | | | | | 150,010 | | | | | | 142,678 | | | | | | 368,688 | | |
Bethany L. Sensenig
|
| | | | 62,500(6) | | | | | | 150,010 | | | | | | 142,678 | | | | | | 355,188 | | |
John M. Siebert, Ph.D.
|
| | | | 46,250(7) | | | | | | 162,520(7) | | | | | | 142,678 | | | | | | 351,448 | | |
Georges Gemayel, Ph.D.,
Bethany Sensenig
SAY-ON-PAY
RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
| | |
2024
|
| |
2023
|
| ||||||
Audit fees
|
| | | $ | 1,854 | | | | | $ | 1,942 | | |
Audit-related fees
|
| | | | — | | | | | | — | | |
Tax fees
|
| | | | — | | | | | | — | | |
All other fees
|
| | | $ | 116 | | | | | | — | | |
Total
|
| | | $ | 1,970 | | | | | $ | 1,942 | | |
![[MISSING IMAGE: px_25supernusproxy1pg1-bw.jpg]](https://www.sec.gov/Archives/edgar/data/0001356576/000110465925042531/px_25supernusproxy1pg1-bw.jpg)
![[MISSING IMAGE: px_25supernusproxy1pg2-bw.jpg]](https://www.sec.gov/Archives/edgar/data/0001356576/000110465925042531/px_25supernusproxy1pg2-bw.jpg)